Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Cancer Immunol Res. 2014 Mar 31;2(7):655–667. doi: 10.1158/2326-6066.CIR-13-0209

Figure 3. Tumor type dictates the composition of myeloid cell subsets within tumors.

Figure 3

A, Myeloid cells within s.c. and mammary gland of transgenic Her2 tumors (n=4–7); within primary s.c. and spontaneous peritoneal metastatic 4T1 tumors (n=3); and within s.c. B16 tumors or lung and kidney metastases (n=3–4). B, Left, Analysis of myeloid subsets within tumors from Balb/c mice with single (Her2 or 4T1, n=5) or double (Her2 and 4T1 on opposite flanks, n=8) tumors. Right, Frequency of myeloid cells in the spleens of tumor-bearing mice. C, Left, Analysis of myeloid cell subsets within tumors from F1 (Balb/c × C57BL/6) mice with single (Her2 or B16, n=3) or double (Her2 and B16 on opposite flanks, n=3) tumors. Right, Frequency of myeloid cells in the spleens of tumor-bearing mice. Numbers indicate percentage of cells for each gate or region. N.S., not significant, * P<0.05, *** P<0.001.